Liu et al. [29] studied the effect of a synthetic broad-spectrum MMP inhibitor (MMPI), prinomastat, in an orthotopic lung cancer model in which tumors express MMP-14, MMP-2, and tissue inhibitor of metalloproteinases-2 (TIMP-2). Here, MMP2 is linked to lung carcinoma.